{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:33Z","timestamp":1793103333474,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Osteoarthritis Research Society International"},{"name":"Osteoarthritis Research Society International"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Samumed"},{"name":"Flexion Therapeutics"},{"name":"EMD-Merck Serono"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006663","name":"NIDR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TissueGene"},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Agios"},{"name":"Omeros"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVBie"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005201","name":"Elsevier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005201","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Walters Kluwer"}],"content-domain":{"domain":["oarsiopenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage Open"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ocarto.2020.100059","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T03:21:11Z","timestamp":1583810471000},"page":"100059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Disease modification in osteoarthritis; pathways to drug approval"],"prefix":"10.1016","volume":"2","author":[{"given":"Jeffrey N.","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh F.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Byers","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ocarto.2020.100059_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ocarto.2020.100059_bib2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/art.24021","article-title":"Lifetime risk of symptomatic knee osteoarthritis","volume":"59","author":"Murphy","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ocarto.2020.100059_bib3","series-title":"Healthcare cost and utilization project (HCUP)","volume":"vol. 2019","author":"HCUPnet","year":"2019"},{"key":"10.1016\/j.ocarto.2020.100059_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2474-9-95","article-title":"Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee","volume":"9","author":"van Dijk","year":"2008","journal-title":"BMC Muscoskel. Disord."},{"key":"10.1016\/j.ocarto.2020.100059_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2003.007526","article-title":"Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales","volume":"63","author":"Kadam","year":"2004","journal-title":"Ann. Rheum. Dis"},{"key":"10.1016\/j.ocarto.2020.100059_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.joca.2018.12.008","article-title":"The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up","volume":"27","author":"Cleveland","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ocarto.2020.100059_bib7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.joca.2015.03.012","article-title":"OARSI Clinical Trials Recommendations: knee imaging in clinical trials in osteoarthritis","volume":"23","author":"Hunter","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ocarto.2020.100059_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000163","article-title":"Conventional and novel imaging modalities in osteoarthritis: current state of the evidence","volume":"27","author":"Demehri","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.ocarto.2020.100059_bib9","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/art.39324","article-title":"Brief report: cartilage thickness change as an imaging biomarker of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium","volume":"67","author":"Eckstein","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ocarto.2020.100059_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/annrheumdis-2013-203631","article-title":"What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?","volume":"72","author":"Pelletier","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ocarto.2020.100059_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/annrheumdis-2011-201164","article-title":"Quantitative MRI measures of cartilage predict knee replacement: a case-control study from the Osteoarthritis Initiative","volume":"72","author":"Eckstein","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ocarto.2020.100059_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/annrheumdis-2013-204052","article-title":"A\u00a0novel method for bone area measurement provides new insights into osteoarthritis and its progression","volume":"74","author":"Bowes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ocarto.2020.100059_bib13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/kew191","article-title":"The relationship between three-dimensional knee MRI bone shape and total knee replacement-a case control study: data from the Osteoarthritis Initiative","volume":"55","author":"Barr","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.ocarto.2020.100059_bib14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2015-207602","article-title":"Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium","volume":"75","author":"Hunter","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ocarto.2020.100059_bib15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ocarto.2020.100059_bib16","series-title":"Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. Annals of Internal Medicine","author":"Conaghan","year":"2019"},{"key":"10.1016\/j.ocarto.2020.100059_bib17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.joca.2017.07.006","article-title":"A\u00a0novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study","volume":"25","author":"Yazici","year":"2017","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ocarto.2020.100059_bib18","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.joca.2019.02.046","article-title":"Biomarkers of bone and cartilage turnover CTX-I and CTX-II predict total joint replacements in osteoarthritis","volume":"27","author":"Bjerre-Bastos","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ocarto.2020.100059_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/annrheumdis-2016-209252","article-title":"Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium","volume":"76","author":"Kraus","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ocarto.2020.100059_bib20","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.joca.2019.02.095","article-title":"Identification of superior responders to a bone and cartilage centric treatment in osteoarthritis: low levels of cartilage formation may provide an opportunity to stimulate formation","volume":"27","author":"Luo","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ocarto.2020.100059_bib21","series-title":"Services USDoHaH","article-title":"Guidance for industry expedited programs for serious conditions \u2013 drugs and biologics","author":"Administration","year":"2014"},{"key":"10.1016\/j.ocarto.2020.100059_bib22","series-title":"Services USDoHaH","article-title":"Osteoarthritis: structural endpoints for the development of drugs, devices, and biological products for treatment guidance for industry","author":"Administration","year":"2018"},{"key":"10.1016\/j.ocarto.2020.100059_bib23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12891-016-1310-6","article-title":"Semi-quantitative MRI biomarkers of knee osteoarthritis progression in the FNIH biomarkers consortium cohort\u2009-\u2009Methodologic aspects and definition of change","volume":"17","author":"Roemer","year":"2016","journal-title":"BMC Muscoskel. Disord."},{"key":"10.1016\/j.ocarto.2020.100059_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.joca.2018.11.002","article-title":"Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs","volume":"27","author":"Kraus","year":"2019","journal-title":"Osteoarthritis Cartilage"}],"container-title":["Osteoarthritis and Cartilage Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665913120300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665913120300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:20:16Z","timestamp":1762939216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2665913120300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2665913120300480"],"URL":"https:\/\/doi.org\/10.1016\/j.ocarto.2020.100059","relation":{},"ISSN":["2665-9131"],"issn-type":[{"value":"2665-9131","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease modification in osteoarthritis; pathways to drug approval","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocarto.2020.100059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International (OARSI).","name":"copyright","label":"Copyright"}],"article-number":"100059"}}